Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, Bowtell DD; Australian Ovarian Cancer Study Group; Gorringe KL, Campbell IG. Ryland GL, et al. Among authors: bowtell dd. J Pathol. 2013 Feb;229(3):469-76. doi: 10.1002/path.4134. J Pathol. 2013. PMID: 23096461
High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ; Australian Ovarian Cancer Study Group; DeFazio A, Fox SB, Brenton JD, Bowtell DD, Dobrovic A. Krypuy M, et al. Among authors: bowtell dd. BMC Cancer. 2007 Aug 31;7:168. doi: 10.1186/1471-2407-7-168. BMC Cancer. 2007. PMID: 17764544 Free PMC article.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group; Gertig D, DeFazio A, Bowtell DD. Tothill RW, et al. Among authors: bowtell dd. Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. Clin Cancer Res. 2008. PMID: 18698038
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ; AOCS Study Group; deFazio A, Chenevix-Trench G, Bowtell DD. Anglesio MS, et al. Among authors: bowtell dd. Mol Cancer Res. 2008 Nov;6(11):1678-90. doi: 10.1158/1541-7786.MCR-08-0193. Mol Cancer Res. 2008. PMID: 19010816 Free PMC article.
Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.
Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD; Australian Ovarian Cancer Study. Gorringe KL, et al. Among authors: bowtell dd. PLoS One. 2010 Sep 10;5(9):e11408. doi: 10.1371/journal.pone.0011408. PLoS One. 2010. PMID: 20844748 Free PMC article.
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M; Australian Ovarian Cancer Study Group; Gorringe KL, Smyth GK, Bowtell DD. Etemadmoghadam D, et al. Among authors: bowtell dd. PLoS One. 2010 Nov 12;5(11):e15498. doi: 10.1371/journal.pone.0015498. PLoS One. 2010. PMID: 21103391 Free PMC article.
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group; Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. Anglesio MS, et al. Among authors: bowtell dd. Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22. Clin Cancer Res. 2011. PMID: 21343371 Clinical Trial.
362 results